BioMed Research International / 2014 / Article / Tab 3

Review Article

The Role of MicroRNAs in Ovarian Cancer

Table 3

Potential therapeutic miRs for ovarian cancer.

miRNATarget geneCellular functionOvarian cancer cell lineReference

miR-200 familymiR-141KEEP1Cisplatin resistanceA2780 (EOC), TOV112D (EAC), TOV21G (CAC)[61]
miR-141, miR-200aMAPK14Oxidative stress response, pactitaxel sensitivitySKOV3 (EOC)[55]
miR-200aZEB2EMT, stemness, migration, invasionOVCAR3 (EOC)[56]
miR-200cZEB1, TUBB3EMT, stemness, adhesion, migration, invasion, paclitaxel sensitivityHEY (SAC), SKOV3 (EOC)[57, 59, 60]
miR-200a, miR-200bIL8, CXCL1AngiogenesisHeyA8 (SAC), ES2 (CAC)[58]

miR-199/214 clustermiR-199a-5pIKKB, HIF-1A, HIF-2AInflammation, chemosensitivity, migration, metastasisA2780 (EOC), R454 (EOC), 01-28 (EOC), R182 (EOC), 01-19B (EOC), R1185 (EOC), primary culture[62, 63, 67]
miR-199a-3pCD44Stemness, chemosensitivityprimary culture[64]
miR-199b-5pJAG1Cisplatin sensitivityA2780 (EOC), OV119 (EOC)[65]
miR-214PTEN, CCL5Proliferation, cell survival, cisplatin resistance, CAFs activityA2780 (EOC), HeyA8 (SAC), SKOV3ip1 (EOC), OV119 (EOC), primary culture[63, 66, 87]

let-7HMGA2CarcinogenesisA2780 (EOC), HeyA8 (SAC), IGROV-1 (EOC)[69, 70]

miR-506SNAI2EMTHeyA8 (SAC), SKOV3 (EOC), OVCA420 (EOC), OVCA433 (EOC)[26]
CDK4, CDK6Proliferation, senescenceHeyA8 (SAC), SKOV3 (EOC), OVCA432 (EOC), OVCA433 (EOC)[73]

miR-92aITGA5Adhesion, invasion, proliferationA2780 (EOC), SKOV3ip1 (EOC), OVISE (CAC)[74]

miR-31METPaclitaxel sensitivityKFr13 (EOC)[76]
CEBPA, STK40, E2F2ProliferationSKOV3 (EOC), OVCAR8 (EOC), OVCA433 (EOC)[77]

miR-484VEGFB, VEGFR2AngiogenesisSKOV3 (EOC), MDAH-2274 (EOC)[78]

miR-502d-3pEPHA2, EPHB2Proliferation, migration, invasionHeyA8 (SAC), SKOV3ip1 (EOC), ES2 (CAC)[79]

miR-155SATB1, CD200DCs activityID8 (EOC, mouse)[90]

CAFs: cancer associated fibroblasts; EMT: epithelial-mesenchymal transition; DCs: dendritic cells; EOC: epithelial ovarian cancer; EAC: endometrioid adenocarcinoma; CAC: clear cell adenocarcinoma; SAC: serous adenocarcinoma.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.